SELENA BOYD: Open Payments
NPI 1942481601 · ELIZABETHTOWN, KY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$639 in 34 payments from 10 companies in 2025. Trend: 2023 $0 · 2024 $231 · 2025 $639
Food & beverage: $639
| Company | Payments | Amount |
|---|---|---|
| Insmed, Inc. | 12 | $235 |
| Viatris Specialty LLC | 5 | $94 |
| AstraZeneca Pharmaceuticals LP | 5 | $85 |
| GlaxoSmithKline, LLC. | 3 | $54 |
| Actelion Pharmaceuticals US, Inc. | 2 | $46 |
| Merck Sharp & Dohme LLC | 2 | $33 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $30 |
| Grifols USA, LLC | 1 | $28 |
| PFIZER INC. | 1 | $19 |
| United Therapeutics Corporation | 1 | $16 |
Products named: Arikayce, YUPELRI, NUCALA, UPTRAVI, FASENRA, ZERBAXA, ARALAST, Prolastin-C Liquid.
Industry payments across KY — which companies pay providers there.
